Situation: A public health nurse at a Rural Health Unit (RHU) manages clients enrolled in the National Tuberculosis Program (NTP). Many of them live in crowded urban households. A 27-year-old woman in the intensive phase of treatment for tuberculosis, which includes rifampicin, uses combined oral contraceptive pills. She does not want to become pregnant. What should the nurse advise?

Rifampicin is a strong liver enzyme inducer that lowers the blood levels of hormonal contraceptives and can lead to contraceptive failure. During treatment the client should use a method not affected by this interaction, such as a copper intrauterine device, DMPA, or a barrier method, and continue it for 4 weeks after the last dose of rifampicin, because the enzyme induction wears off slowly. Switching to another oral hormonal pill does not solve the problem.

The core issue in this scenario is a clinically significant drug–drug interaction between rifampicin and combined oral contraceptives (COCs). Rifampicin is a potent inducer of hepatic cytochrome P450 enzymes, particularly CYP3A4, which accelerates the metabolism of ethinyl estradiol and progestins. This lowers serum hormone levels and can result in contraceptive failure, even when the pill is taken consistently and at the same time each day ^[1][4].

Because the interaction is pharmacokinetic rather than adherence-related, simply continuing the COC or switching to another oral hormonal formulation does not restore reliable contraception. The enzyme-inducing effect persists for several weeks after rifampicin is discontinued, so protection must be maintained with a non-hormonal or enzyme-independent method during treatment and for 4 weeks after the last rifampicin dose ^[1].

Among the options, the copper intrauterine device (Cu-IUD) is the most appropriate recommendation. It provides contraception through a local, non-hormonal mechanism—copper ions are spermicidal and impair fertilization—without relying on hepatic metabolism. Therefore, its efficacy is unaffected by rifampicin ^[1]. In contrast, progestin-only pills (POPs) are also susceptible to enzyme induction because their progestin component is metabolized by CYP3A4; rifampicin can significantly reduce POP hormone levels and increase the risk of ovulation ^[1]. Adding condoms for only the first week does not address the ongoing interaction throughout the intensive phase and the post-treatment washout period.

Method	Interaction with rifampicin	Reliability during TB treatment
Copper IUD	None; non-hormonal, local action	High; preferred option
DMPA (depot medroxyprogesterone acetate)	Minimal; progestin levels may be less affected than COCs	Acceptable alternative
Combined oral contraceptive	Strong enzyme induction lowers estrogen and progestin levels	Unreliable; avoid
Progestin-only pill	Enzyme induction lowers progestin levels	Unreliable; avoid
Barrier method (condom)	None	Reliable if used consistently and correctly

Key point! Rifampicin reduces hormonal contraceptive efficacy by increasing hepatic clearance, not by interfering with pill absorption or timing. Therefore, adherence strategies such as taking the pill at the same hour daily do not overcome the interaction.

Watch out! The enzyme-inducing effect does not stop immediately when rifampicin is discontinued. The client must continue using a non-hormonal method for 4 weeks after the final dose to avoid unintended pregnancy ^[1].

For a client who does not want to become pregnant and is in the intensive phase of TB treatment, the safest and most evidence-based advice is to switch to a copper IUD during treatment and for the recommended post-treatment interval. This approach avoids the drug interaction entirely and provides long-acting, reversible contraception without hormonal exposure.